{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:06:44Z","timestamp":1792796804856,"version":"4.5.0"},"reference-count":150,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Primary hyperparathyroidism (PHPT) is a common endocrinopathy, predominantly caused by a single parathyroid adenoma that is responsible for the excessive secretion of parathyroid hormone (PTH)\u2014the hallmark of disease. Excess of this hormone causes remarkable changes in bone metabolism, including an increased level of bone remodeling with a predominance of bone resorption. Those changes lead to deterioration of bone structure and density, especially in cortical bone. The main treatment for PHPT is surgical removal of the adenoma, which normalizes PTH levels and terminates the progression of bone disease and leads to its regeneration. However, because not all the patients are suitable candidates for surgery, alternative therapies are needed. Current non-surgical treatments targeting bone disease secondary to PHPT include bisphosphonates and denosumab. Those antiresorptives prevent further bone loss, but they lack the ability to regenerate already degraded bone. There is ongoing research to find targeted drugs capable of halting resorption alongside stimulating bone formation. This review presents the advancements in understanding the molecular mechanisms responsible for bone disease in PHPT and assesses the efficacy of new potential therapeutic approaches (e.g., allosteric inhibitors of the PTH receptor, V-ATPase, or cathepsin inhibitors) aimed at mitigating bone loss and enhancing bone regeneration in affected patients.<\/jats:p>","DOI":"10.3390\/ijms252111639","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T12:25:39Z","timestamp":1730291139000},"page":"11639","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Bone Disease in Primary Hyperparathyroidism\u2014Changes Occurring in Bone Metabolism and New Potential Treatment Strategies"],"prefix":"10.3390","volume":"25","author":[{"given":"Mirella","family":"Iwanowska","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Kochman","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Szatko","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland"},{"name":"EndoLab Laboratory, Centre of Postgraduate Medical Education, 01-809 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Zgliczy\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Glinicki","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland"},{"name":"EndoLab Laboratory, Centre of Postgraduate Medical Education, 01-809 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1002\/jbmr.4665","article-title":"Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism","volume":"37","author":"Minisola","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s12105-008-0088-8","article-title":"Parathyroid adenoma","volume":"2","author":"Wieneke","year":"2008","journal-title":"Head Neck Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1530\/eje.0.1480403","article-title":"Decrease in vitamin D receptor and calcium-sensing receptor in highly proliferative parathyroid adenomas","volume":"148","author":"Yano","year":"2003","journal-title":"Eur. J. Endocrinol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Christensen, M.H., Apalset, E.M., Nordb\u00f8, Y., Varhaug, J.E., Mellgren, G., and Lien, E.A. (2013). 1,25-Dihydroxyvitamin D and the vitamin D receptor gene polymorphism Apa1 influence bone mineral density in primary hyperparathyroidism. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056019"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2265.2007.03109.x","article-title":"Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism","volume":"68","author":"Moosgaard","year":"2008","journal-title":"Clin. Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1590\/0004-2730000003381","article-title":"Bone disease in primary hyperparathyroidism","volume":"58","author":"Bandeira","year":"2014","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e10482","DOI":"10.1002\/jbm4.10482","article-title":"The Risk of Fractures in Primary Hyperparathyroidism: A Meta-Analysis","volume":"5","author":"Narayanan","year":"2021","journal-title":"JBMR Plus"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00198-021-05822-9","article-title":"Risk of fractures in primary hyperparathyroidism: A systematic review and meta-analysis","volume":"32","author":"Rolighed","year":"2021","journal-title":"Osteoporos. Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.beem.2013.02.006","article-title":"Role of the calcium-sensing receptor in extracellular calcium homeostasis","volume":"27","author":"Brown","year":"2013","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1308\/rcsann.2017.0092","article-title":"Changes in bone turnover markers in primary hyperparathyroidism and response to surgery","volume":"99","author":"Rajeev","year":"2017","journal-title":"Ann. R. Coll. Surg. Engl."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jocd.2012.11.004","article-title":"Bone turnover markers in primary hyperparathyroidism","volume":"16","author":"Costa","year":"2013","journal-title":"J. Clin. Densitom."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e210456","DOI":"10.1530\/EC-21-0456","article-title":"Bone phenotypes in multiple endocrine neoplasia type 1: Survey on the MEN1 Florentine database","volume":"11","author":"Marini","year":"2022","journal-title":"Endocr. Connect."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Marini, F., Giusti, F., Cioppi, F., Maraghelli, D., Cavalli, T., Tonelli, F., and Brandi, M.L. (2021). Bone and mineral metabolism phenotypes in MEN1-related and sporadic primary hyperparathyroidism, before and after parathyroidectomy. Cells, 10.","DOI":"10.3390\/cells10081895"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.otc.2004.02.005","article-title":"Hyperparathyroidism and multiple endocrine neoplasia","volume":"37","author":"Malone","year":"2004","journal-title":"Otolaryngol. Clin. N. Am."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00223-014-9877-0","article-title":"Increased trabecular volumetric bone mass density in Familial Hypocalciuric Hypercalcemia (FHH) type 1: A cross-sectional study","volume":"95","author":"Jakobsen","year":"2014","journal-title":"Calcif. Tissue Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00223-011-9517-x","article-title":"Forearm bone mineral density in familial hypocalciuric hypercalcemia and primary hyperparathyroidism: A comparative study","volume":"89","author":"Isaksen","year":"2011","journal-title":"Calcif. Tissue Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/jbmr.4677","article-title":"Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop","volume":"37","author":"Bilezikian","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1590\/S0004-27302010000200002","article-title":"Bone histomorphometry: A concise review for endocrinologists and clinicians","volume":"54","author":"Kulak","year":"2010","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.eprac.2021.08.006","article-title":"Bone Analysis Using Trabecular Bone Score and Dual-Energy X-Ray Absorptiometry-Based 3-Dimensional Modeling in Postmenopausal Women With Primary Hyperparathyroidism","volume":"28","year":"2022","journal-title":"Endocr. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/jbmr.1841","article-title":"Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women","volume":"28","author":"Stein","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2004.01422.x","article-title":"Primary hyperparathyroidism: New concepts in clinical, densitometric and biochemical features","volume":"257","author":"Bilezikian","year":"2005","journal-title":"J. Intern. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1530\/EJE-13-0305","article-title":"Bone quality, as measured by trabecular bone score, in patients with primary hyperparathyroidism","volume":"169","author":"Filopanti","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/jbmr.98","article-title":"Effects on bone geometry, density, and microarchitecture in the distal radius but not the tibia in women with primary hyperparathyroidism: A case-control study using HR-pQCT","volume":"25","author":"Hansen","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1210\/endo.142.9.8356","article-title":"Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation","volume":"142","author":"Ma","year":"2001","journal-title":"Endocrinology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jcb.10490","article-title":"Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone","volume":"89","author":"Locklin","year":"2003","journal-title":"J. Cell. Biochem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"50259","DOI":"10.1074\/jbc.M307444200","article-title":"Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism","volume":"278","author":"Bellido","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1210\/en.2005-0239","article-title":"Chronic Elevation of Parathyroid Hormone in Mice Reduces Expression of Sclerostin by Osteocytes: A Novel Mechanism for Hormonal Control of Osteoblastogenesis","volume":"146","author":"Bellido","year":"2005","journal-title":"Endocrinology"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Zhu, M., Sun, B.H., Nevius, E., Kaplan, J., Pereira, J., and Insogna, K. (2021). Selective deletion of the receptor for CSF1, c-fms, in osteoclasts results in a high bone mass phenotype, smaller osteoclasts in vivo and an impaired response to an anabolic PTH regimen. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0247199"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"48868","DOI":"10.1074\/jbc.M208494200","article-title":"Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein","volume":"277","author":"Fu","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bone.2007.03.017","article-title":"Molecular and cellular mechanisms of the anabolic effect of intermittent PTH","volume":"40","author":"Jilka","year":"2007","journal-title":"Bone"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: Different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/bonekey.2014.24","article-title":"Bisphosphonates and bone quality","volume":"3","author":"Pazianas","year":"2014","journal-title":"Bonekey Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1210\/jc.2009-1472","article-title":"Cinacalcet treatment of primary hyperparathyroidism: Biochemical and bone densitometric outcomes in a five-year study","volume":"94","author":"Peacock","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1245\/s10434-011-2065-9","article-title":"Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use","volume":"19","author":"Norman","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12020-011-9459-0","article-title":"Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism","volume":"39","author":"Faggiano","year":"2011","journal-title":"Endocr"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S2213-8587(20)30063-2","article-title":"Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Leere","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1210\/jc.2015-2022","article-title":"Vitamin D in primary hyperparathyroidism: Effects on clinical, biochemical, and densitometric presentation","volume":"100","author":"Walker","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1177\/0004563214564400","article-title":"Impact of vitamin D replacement in patients with normocalcaemic and hypercalcaemic primary hyperparathyroidism and coexisting vitamin D deficiency","volume":"52","author":"Das","year":"2015","journal-title":"Ann. Clin. Biochem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/jcb.20388","article-title":"Normal human osteoclasts formed from peripheral blood monocytes express PTH type 1 receptors and are stimulated by PTH in the absence of osteoblasts","volume":"95","author":"Dempster","year":"2005","journal-title":"J. Cell. Biochem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1359\/jbmr.2001.16.3.448","article-title":"Parathyroid hormone\/parathyroid hormone-related peptide type 1 receptor in human bone","volume":"16","author":"Langub","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"ref_41","first-page":"552","article-title":"PTH and stem cells","volume":"34","author":"Ohishi","year":"2011","journal-title":"J. Endocrinol. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1210\/en.2014-1046","article-title":"Parathyroid hormone receptor signaling induces bone resorption in the adult skeleton by directly regulating the RANKL gene in osteocytes","volume":"155","author":"Tu","year":"2014","journal-title":"Endocrinology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S8756-3282(03)00202-3","article-title":"Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure","volume":"33","author":"Frolik","year":"2003","journal-title":"Bone"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"33086","DOI":"10.1074\/jbc.M705194200","article-title":"Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis","volume":"282","author":"Li","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"E841","DOI":"10.1152\/ajpendo.00599.2011","article-title":"The calcium-sensing receptor complements parathyroid hormone-induced bone turnover in discrete skeletal compartments in mice","volume":"302","author":"Xue","year":"2012","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3892\/ijmm.2015.2423","article-title":"Bovine parathyroid hormone enhances osteoclast bone resorption by modulating V-ATPase through PTH1R","volume":"37","author":"Liu","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.cellsig.2010.10.008","article-title":"Antagonist minigenes identify genes regulated by parathyroid hormone through G protein-selective and G protein co-regulated mechanisms in osteoblastic cells","volume":"23","author":"Wang","year":"2011","journal-title":"Cell Signal."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.cellsig.2009.02.012","article-title":"PTH and PTHrP signaling in osteoblasts","volume":"21","author":"Datta","year":"2009","journal-title":"Cell Signal."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrendo.2015.139","article-title":"PTH receptor-1 signalling-mechanistic insights and therapeutic prospects","volume":"11","author":"Cheloha","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s41589-021-00929-w","article-title":"Precise druggability of the PTH type 1 receptor","volume":"18","author":"Sutkeviciute","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1016\/j.bmcl.2019.07.052","article-title":"Discovery of novel PTHR1 antagonists: Design, synthesis, and structure activity relationships","volume":"29","author":"Arai","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Arai, Y., Kiyotsuka, Y., Kagechika, K., Nishi, T., Inui, M., Nagamochi, M., Oyama, K., and Izumi, M. (2020). Discovery of novel, potent, and orally bioavailable pyrido[2,3-d][1]benzazepin-6-one antagonists for parathyroid hormone receptor 1. Bioorg. Med. Chem., 28.","DOI":"10.1016\/j.bmc.2020.115524"},{"key":"ref_53","unstructured":"Choppin, A., Bedinger, D., Hunt, R., Tran, C., Wijesuriya, S., Cotter, R., Pongo, E., Shimizu, R., Chen, J., and Pham, K. (2017, January 1\u20134). A Novel anti-PTH1R Receptor Antagonist Monoclonal Antibody Reverses Hypercalcemia Induced by PTH or PTHrP: A Potential Treatment of Primary Hyperparathyroidism and Humoral Hypercalcemia of Malignancy. Proceedings of the ENDO 2017, Orlando, FL, USA."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Li, M., Bao, Y., Xu, R., Li, M., Xi, L., and Guo, J. (2022). Understanding the Allosteric Modulation of PTH1R by a Negative Allosteric Modulator. Cells, 12.","DOI":"10.3390\/cells12010041"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/jbmr.3600","article-title":"IL-17 Receptor Signaling in Osteoblasts\/Osteocytes Mediates PTH-Induced Bone Loss and Enhances Osteocytic RANKL Production","volume":"34","author":"Li","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"ref_56","first-page":"801","article-title":"Catabolic and anabolic actions of parathyroid hormone on the skeleton","volume":"34","author":"Silva","year":"2011","journal-title":"J. Endocrinol. Investig."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"44347","DOI":"10.1074\/jbc.M202009200","article-title":"A RANK\/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function","volume":"277","author":"Armstrong","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.bbrc.2007.06.017","article-title":"TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation","volume":"359","author":"Lamothe","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Lee, K., Seo, I., Choi, M.H., and Jeong, D. (2018). Roles of Mitogen-Activated Protein Kinases in Osteoclast Biology. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19103004"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1196\/annals.1402.071","article-title":"The role of NFAT in osteoclast formation","volume":"1116","author":"Takayanagi","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41413-020-00120-2","article-title":"MEF2C regulates osteoclastogenesis and pathologic bone resorption via c-FOS","volume":"9","author":"Fujii","year":"2021","journal-title":"Bone Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/nm1515","article-title":"Regulation of osteoclast differentiation and function by the CaMK-CREB pathway","volume":"12","author":"Sato","year":"2006","journal-title":"Nat. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1083\/jcb.201403138","article-title":"HDAC4 integrates PTH and sympathetic signaling in osteoblasts","volume":"205","author":"Obri","year":"2014","journal-title":"J. Cell Biol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Maisuria, R., Norton, A., Shao, C., Bradley, E.W., and Mansky, K. (2023). Conditional Loss of MEF2C Expression in Osteoclasts Leads to a Sex-Specific Osteopenic Phenotype. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241612686"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bone.2004.03.012","article-title":"Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: Effect of parathyroidectomy and association with bone metabolism","volume":"35","author":"Stilgren","year":"2004","journal-title":"Bone"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jama.292.4.490","article-title":"Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases","volume":"292","author":"Hofbauer","year":"2004","journal-title":"JAMA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s12020-023-03381-z","article-title":"Denosumab for osteoporosis in patients with primary hyperparathyroidism and mild-to-moderate renal insufficiency","volume":"81","author":"Gronskaya","year":"2023","journal-title":"Endocrine"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s12020-020-02401-6","article-title":"Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism","volume":"69","author":"Miyaoka","year":"2020","journal-title":"Endocrine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/jgs.15250","article-title":"Protective effect of denosumab on bone in older women with primary hyperparathyroidism","volume":"66","author":"Palmieri","year":"2018","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"709024","DOI":"10.1155\/2014\/709024","article-title":"Association between parathyroid hormone levels and inflammatory markers among US adults","volume":"2014","author":"Cheng","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000334588","article-title":"Inflammatory biomarkers in patients with asymptomatic primary hyperparathyroidism","volume":"21","author":"Emam","year":"2012","journal-title":"Med. Princ. Pract."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2249.2004.02419.x","article-title":"Interleukin-6 production and secretion by human parathyroids","volume":"136","author":"Safley","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Pacifici, R. (2016). The Role of IL-17 and TH17 Cells in the Bone Catabolic Activity of PTH. Front. Immunol., 7.","DOI":"10.3389\/fimmu.2016.00057"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Tawfeek, H., Bedi, B., Li, J.Y., Adams, J., Kobayashi, T., Weitzmann, M.N., Kronenberg, H.M., and Pacifici, R. (2010). Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012290"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1210\/en.2011-1515","article-title":"An irradiation-altered bone marrow microenvironment impacts anabolic actions of PTH","volume":"152","author":"Koh","year":"2011","journal-title":"Endocrinology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar2936","article-title":"Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors","volume":"12","author":"Adamopoulos","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.cmet.2015.09.012","article-title":"IL-17A Is Increased in Humans with Primary Hyperparathyroidism and Mediates PTH-Induced Bone Loss in Mice","volume":"22","author":"Li","year":"2015","journal-title":"Cell Metab."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Chen, T.L., Chang, K.H., and Su, K.Y. (2022). Effects of Biological\/Targeted Therapies on Bone Mineral Density in Inflammatory Arthritis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084111"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"21971","DOI":"10.1074\/jbc.M200434200","article-title":"Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B","volume":"277","author":"Cappellen","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4068\/cmj.2016.52.1.12","article-title":"Signaling Pathways in Osteoclast Differentiation","volume":"52","author":"Kim","year":"2016","journal-title":"Chonnam Med. J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"18991","DOI":"10.1074\/jbc.M610937200","article-title":"M-CSF regulates the cytoskeleton via recruitment of a multimeric signaling complex to c-Fms Tyr-559\/697\/721","volume":"282","author":"Faccio","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Siddiqui, J.A., Johnson, J., Le Henaff, C., Bitel, C.L., Tamasi, J.A., and Partridge, N.C. (2017). Catabolic Effects of Human PTH (1\u201334) on Bone: Requirement of Monocyte Chemoattractant Protein-1 in Murine Model of Hyperparathyroidism. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-15563-7"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1189\/jlb.2A0114-006R","article-title":"Pleiotropic effects of extended blockade of CSF1R signaling in adult mice","volume":"96","author":"Sauter","year":"2014","journal-title":"J. Leukoc. Biol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Nara, Y., Kitaura, H., Ogawa, S., Shen, W.R., Qi, J., Ohori, F., Noguchi, T., Marahleh, A., Pramusita, A., and Kinjo, R. (2020). Anti-c-fms Antibody Prevents Osteoclast Formation and Bone Resorption in Co-Culture of Osteoblasts and Osteoclast Precursors In Vitro and in Ovariectomized Mice. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176120"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1007\/s43440-020-00091-5","article-title":"Blockade of the colony-stimulating factor-1 receptor reverses bone loss in osteoporosis mouse models","volume":"72","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.4158\/EP14104.OR","article-title":"Serum monocyte chemokine protein-1 levels before and after parathyroidectomy in patients with primary hyperparathyroidism","volume":"20","author":"Patel","year":"2014","journal-title":"Endocr. Pract."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1210\/jc.2010-2781","article-title":"The high serum monocyte chemoattractant protein-1 in obesity is influenced by high parathyroid hormone and not adiposity","volume":"96","author":"Sukumar","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"33098","DOI":"10.1074\/jbc.M611781200","article-title":"Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre\/osteoclasts","volume":"282","author":"Li","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbrc.2009.04.020","article-title":"MCP-1 expressed by osteoclasts stimulates osteoclastogenesis in an autocrine\/paracrine manner","volume":"383","author":"Miyamoto","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"16163","DOI":"10.1074\/jbc.M412713200","article-title":"MCP-1 is induced by receptor activator of nuclear factor-{kappa}B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation","volume":"280","author":"Kim","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/jcp.22879","article-title":"Absence of MCP-1 leads to elevated bone mass via impaired actin ring formation","volume":"227","author":"Sul","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/jcb.24663","article-title":"Dominant negative MCP-1 blocks human osteoclast differentiation","volume":"115","author":"Morrison","year":"2014","journal-title":"J. Cell. Biochem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5312\/wjo.v4.i4.198","article-title":"Role of osteoclasts in regulating hematopoietic stem and progenitor cells","volume":"4","author":"Miyamoto","year":"2013","journal-title":"World J. Orthop."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1242\/jcs.113.3.377","article-title":"The cell biology of osteoclast function","volume":"113","author":"Zhao","year":"2000","journal-title":"J. Cell Sci."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Kim, J.M., Lin, C., Stavre, Z., Greenblatt, M.B., and Shim, J.H. (2020). Osteoblast-Osteoclast Communication and Bone Homeostasis. Cells, 9.","DOI":"10.3390\/cells9092073"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00774-007-0773-9","article-title":"Involvement of alpha(v)beta3 integrins in osteoclast function","volume":"25","author":"Nakamura","year":"2007","journal-title":"J. Bone Miner. Metab."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.0105-2896.2005.00335.x","article-title":"The role(s) of Src kinase and Cbl proteins in the regulation of osteoclast differentiation and function","volume":"208","author":"Horne","year":"2005","journal-title":"Immunol. Rev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1083\/jcb.200611083","article-title":"Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption","volume":"176","author":"Zou","year":"2007","journal-title":"J. Cell Biol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nm1194","article-title":"Vav3 regulates osteoclast function and bone mass","volume":"11","author":"Faccio","year":"2005","journal-title":"Nat. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1538-7836.2009.03378.x","article-title":"The structure and function of platelet integrins","volume":"7","author":"Bennett","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1172\/JCI8905","article-title":"Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts","volume":"105","author":"McHugh","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejphar.2017.03.019","article-title":"Inhibition of osteoporosis by the \u03b1v\u03b23 integrin antagonist of rhodostomin variants","volume":"804","author":"Lin","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Zur, Y., Rosenfeld, L., Keshelman, C.A., Dalal, N., Guterman-Ram, G., Orenbuch, A., Einav, Y., Levaot, N., and Papo, N. (2018). A dual-specific macrophage colony-stimulating factor antagonist of c-FMS and \u03b1v\u03b23 integrin for osteoporosis therapy. PLoS Biol., 16.","DOI":"10.1371\/journal.pbio.2002979"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.biocel.2012.05.014","article-title":"V-ATPases in osteoclasts: Structure, function and potential inhibitors of bone resorption","volume":"44","author":"Qin","year":"2012","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jcb.24434","article-title":"Luteolin inhibition of V-ATPase a3-d2 interaction decreases osteoclast resorptive activity","volume":"114","author":"Crasto","year":"2013","journal-title":"J. Cell. Biochem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.7150\/thno.28391","article-title":"V-ATPases and osteoclasts: Ambiguous future of V-ATPases inhibitors in osteoporosis","volume":"8","author":"Duan","year":"2018","journal-title":"Theranostics"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Holliday, L.S. (2017). Vacuolar H+-ATPases (V-ATPases) as therapeutic targets: A brief review and recent developments. Biotarget, 1.","DOI":"10.21037\/biotarget.2017.12.01"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1172\/JCI6145","article-title":"A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats","volume":"106","author":"Visentin","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1359\/JBMR.050517","article-title":"A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: Potential for clinical application","volume":"20","author":"Niikura","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"10126","DOI":"10.1111\/jcmm.16949","article-title":"Bisphosphonate-enoxacin inhibit osteoclast formation and function by abrogating RANKL-induced JNK signalling pathways during osteoporosis treatment","volume":"25","author":"Xu","year":"2021","journal-title":"J. Cell Mol. Med."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Liu, X., Qu, X., Nie, T., Zhai, Z., Li, H., Ouyang, Z., Qin, A., Zhang, S., Zhang, S., and Fan, Q. (2017). The Beneficial Effects of Bisphosphonate-enoxacin on Cortical Bone Mass and Strength in Ovariectomized Rats. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00355"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/jcb.20438","article-title":"Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: An analysis by DNA microarray","volume":"95","author":"Onyia","year":"2005","journal-title":"J. Cell. Biochem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.gene.2009.06.013","article-title":"Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand","volume":"446","author":"Balkan","year":"2009","journal-title":"Gene"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.bone.2008.11.012","article-title":"Periostin-like-factor and Periostin in an animal model of work-related musculoskeletal disorder","volume":"44","author":"Rani","year":"2009","journal-title":"Bone"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.mce.2015.12.014","article-title":"Periostin action in bone","volume":"432","author":"Bonnet","year":"2016","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"35939","DOI":"10.1074\/jbc.M109.060335","article-title":"The matricellular protein periostin is required for sost inhibition and the anabolic response to mechanical loading and physical activity","volume":"284","author":"Bonnet","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Bonnet, N., Gineyts, E., Ammann, P., Conway, S.J., Garnero, P., and Ferrari, S. (2013). Periostin deficiency increases bone damage and impairs injury response to fatigue loading in adult mice. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0078347"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"15048","DOI":"10.1073\/pnas.1203085109","article-title":"Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin","volume":"109","author":"Bonnet","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1007\/s00198-021-06018-x","article-title":"Higher serum levels of a cathepsin K-generated periostin fragment are associated with fractures in postmenopausal women with primary hyperparathyroidism: A pilot study","volume":"32","author":"Pepe","year":"2021","journal-title":"Osteoporos. Int."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/jbmr.3136","article-title":"Cathepsin K Controls Cortical Bone Formation by Degrading Periostin","volume":"32","author":"Bonnet","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/bonekey.2012.67","article-title":"Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation","volume":"1","author":"Duong","year":"2012","journal-title":"Bonekey Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1002\/jbmr.3227","article-title":"An Ectosteric Inhibitor of Cathepsin K Inhibits Bone Resorption in Ovariectomized Mice","volume":"32","author":"Panwar","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/BOR.0b013e32816e06f9","article-title":"The Wnt signaling pathway and bone metabolism","volume":"19","author":"Johnson","year":"2007","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","article-title":"Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation","volume":"8","author":"Glass","year":"2005","journal-title":"Dev. Cell"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: From human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20031454","article-title":"Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist","volume":"199","author":"Roelen","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/jbm4.10021","article-title":"Parathyroid Hormone Signaling in Osteocytes","volume":"2","author":"Wein","year":"2017","journal-title":"JBMR Plus"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"26770","DOI":"10.1074\/jbc.M504308200","article-title":"SOST is a ligand for LRP5\/LRP6 and a Wnt signaling inhibitor","volume":"280","author":"Tamai","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"41614","DOI":"10.1074\/jbc.M110.153890","article-title":"Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways","volume":"285","author":"Krause","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1055\/s-0031-1275661","article-title":"Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia","volume":"119","author":"Kaji","year":"2011","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"20764","DOI":"10.1073\/pnas.0805133106","article-title":"Regulation of bone formation by osteoclasts involves Wnt\/BMP signaling and the chemokine sphingosine-1-phosphate","volume":"105","author":"Pederson","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"O\u2019Brien, C.A., Plotkin, L.I., Galli, C., Goellner, J.J., Gortazar, A.R., Allen, M.R., Robling, A.G., Bouxsein, M., Schipani, E., and Turner, C.H. (2008). Control of Bone Mass and Remodeling by PTH Receptor Signaling in Osteocytes. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0002942"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/jbmr.304","article-title":"PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling","volume":"26","author":"Rhee","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab Treatment in Postmenopausal Women with Osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jbmr.3735","article-title":"Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women with Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis after 2 and 12 Months of Treatment","volume":"34","author":"Chavassieux","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1210\/er.2011-1060","article-title":"Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases","volume":"33","author":"Ke","year":"2012","journal-title":"Endocr. Rev."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Takebe, S., Seki, Y., Yamashita, K., Takano, N., Bokuda, K., Watanabe, D., Morimoto, S., and Ichihara, A. (2024, January 11\u201314). Romosozumab therapy after parathyroidectomy for osteoporosis caused by primary hyperparathyroidism: Two case reports. Proceedings of the 26th European Congress of Endocrinology, Stockholm, Sweden. Endocrine Abstracts.","DOI":"10.1530\/endoabs.99.EP202"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/35083081","article-title":"Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6\/Arrow","volume":"3","author":"Bafico","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0960-9822(01)00290-1","article-title":"Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6","volume":"11","author":"Tamai","year":"2001","journal-title":"Curr. Biol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/nature756","article-title":"Kremen proteins are Dickkopf receptors that regulate Wnt\/beta-catenin signalling","volume":"417","author":"Mao","year":"2002","journal-title":"Nature"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/jcb.20506","article-title":"Effects of parathyroid hormone on Wnt signaling pathway in bone","volume":"95","author":"Kulkarni","year":"2005","journal-title":"J. Cell. Biochem."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cmet.2009.12.007","article-title":"Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation","volume":"11","author":"Guo","year":"2010","journal-title":"Cell Metab."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2010-2552","article-title":"The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1","volume":"96","author":"Gatti","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s00223-012-9665-7","article-title":"Sclerostin and DKK1 in primary hyperparathyroidism","volume":"92","author":"Viapiana","year":"2013","journal-title":"Calcif. Tissue Int."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1002\/jbmr.472","article-title":"Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury","volume":"26","author":"Li","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1124\/jpet.111.181404","article-title":"A rate-limiting role for Dickkopf-1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody","volume":"338","author":"Glantschnig","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nm1538","article-title":"Dickkopf-1 is a master regulator of joint remodeling","volume":"13","author":"Diarra","year":"2007","journal-title":"Nat. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1136\/ard.2010.132852","article-title":"Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression","volume":"69","author":"Heiland","year":"2010","journal-title":"Ann. Rheum. Dis."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/21\/11639\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:23:39Z","timestamp":1760113419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/21\/11639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":150,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["ijms252111639"],"URL":"https:\/\/doi.org\/10.3390\/ijms252111639","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]}}}